发现了第一类的 Aurora B 激酶选择性降解剂
Xiaoping Hu1, Kevin Graciano2, Jianping Hu1
1Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
European journal of medicinal chemistry
|July 29, 2025
概括
研究人员开发了MS44,这是AURKB的第一个选择性降解剂. 这种新型的蛋白质溶解向嵌合体 (PROTAC) 有效地降解了AURKB,抑制了癌细胞的增殖,并提供了潜在的新疗法策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现 药物发现
背景情况:
- 极光激酶 (A,B,C) 对于线粒分裂至关重要,在癌症中经常过度表达.
- 现有的治疗方法包括 Aurora 激酶抑制剂,但缺乏选择性降解剂.
- 报道了极光激酶A (AURKA) 和双重AURKA/AURKB降解剂,但没有AURKB特异性的.
研究的目的:
- 为了发现和描述第一个选择性降解光激酶B (AURKB) 的降解剂.
- 评估该化合物在抑制癌细胞增殖方面的有效性.
- 建立AURKB降解作为癌症潜在的治疗策略.
主要方法:
- 发现MS44,一个·希佩尔-林道 (VHL) E3酶招募蛋白质溶解向的嵌合体 (PROTAC).
- 使用生物化学分析评估AURKB降解,证实VHL和无素-蛋白酶体系统 (UPS) 的依赖.
- 对AURKA和其他酶的化合物18的选择性的评估.
- 测试化合物18对各种癌症细胞系的抗增殖作用.
主要成果:
- MS44 (化合物18) 是第一个报告的AURKB的选择性降解剂.
- 以时间,度,VHL和UPS为依赖的方式,在DC50 < 100 nM下实现AURKB的强烈降解.
- 化合物18对AURKB表现出对AURKA和相关激酶的选择性.
- 在多个癌症细胞系中观察到有效的增殖抑制.
结论:
- 化合物18代表了作为化学生物学工具和潜在治疗剂的重大进步.
- 药理降解AURKB为AURKB依赖性瘤提供了一个有希望的替代治疗方法.
- 这一发现证实了针对癌症治疗的AURKB降解的有效性.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


